Legend Biotech Corporation
LEGN
$19.01
-$0.33-1.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.33% | -589.05% | -68.78% | 118.15% | -101.46% |
| Total Depreciation and Amortization | 50.47% | 9.03% | -9.14% | 34.57% | -16.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -54.63% | -- |
| Total Other Non-Cash Items | -81.03% | 1,654.67% | 368.04% | -164.91% | 6,590.09% |
| Change in Net Operating Assets | 232.60% | -1,255.96% | -178.25% | -682.99% | -1,290.04% |
| Cash from Operations | 137.99% | -689.95% | -768.60% | 14.18% | -24.61% |
| Capital Expenditure | -142.37% | -169.94% | 67.94% | 45.27% | 61.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.53% | 77.42% | 166.33% | -120.75% | 262.57% |
| Cash from Investing | -106.08% | 76.21% | 164.78% | -121.56% | 257.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 48.28% | -8.88% | -2.51% | -407.89% | 32.36% |
| Issuance of Common Stock | -76.48% | -87.09% | -9.13% | -2.90% | 101.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -84.22% | -203.66% | -19.74% | -136.00% | 341.73% |
| Foreign Exchange rate Adjustments | 441.41% | 49,244.44% | 508.16% | -256.46% | 166.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.23% | 74.85% | 140.76% | -154.90% | 195.66% |